BioWorld Asia

Jan. 12, 2011

Biotie Beefs up CNS Pipe with $120M Synosia Buy

LONDON – Biotie Therapies Corp. is acquiring Synosia Therapeutics Holding AG in an all-share deal that values the private Swiss company at €93.6 million (US$120.95 million). (BioWorld International) Read More

Symphogen Financing Largest for Private European Biotech

Immutep Lands $100M License for Autoimmune Drugs with GSK

Human Protein Can Turn on Immune Response to Cancer

Neurosearch Restructures, Preps to Market Huntexil

Cell Medica to Automate Cell Therapy for Commercialization

Spirogen, Genentech Ink Antibody Drug Conjugate Deal

Santaris and Pfizer Agree to $614M RNA Collaboration

Amarin Raises $91.2M in Public Offering for AMR101 Sales Prep

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...